IL250888A0 - Transmuted piperidine compounds - Google Patents
Transmuted piperidine compoundsInfo
- Publication number
- IL250888A0 IL250888A0 IL250888A IL25088817A IL250888A0 IL 250888 A0 IL250888 A0 IL 250888A0 IL 250888 A IL250888 A IL 250888A IL 25088817 A IL25088817 A IL 25088817A IL 250888 A0 IL250888 A0 IL 250888A0
- Authority
- IL
- Israel
- Prior art keywords
- piperidine compounds
- substituted piperidine
- substituted
- compounds
- piperidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048771P | 2014-09-10 | 2014-09-10 | |
| US201462078845P | 2014-11-12 | 2014-11-12 | |
| US201562146790P | 2015-04-13 | 2015-04-13 | |
| PCT/US2015/049235 WO2016040515A1 (en) | 2014-09-10 | 2015-09-09 | Substituted piperidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL250888A0 true IL250888A0 (en) | 2017-04-30 |
Family
ID=55459535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL250888A IL250888A0 (en) | 2014-09-10 | 2017-03-02 | Transmuted piperidine compounds |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10577363B2 (enExample) |
| EP (1) | EP3193605A4 (enExample) |
| JP (1) | JP2017528464A (enExample) |
| KR (1) | KR20170047397A (enExample) |
| CN (1) | CN107072207A (enExample) |
| AU (1) | AU2015315182A1 (enExample) |
| BR (1) | BR112017004589A2 (enExample) |
| CA (1) | CA2960280A1 (enExample) |
| EA (1) | EA201790327A1 (enExample) |
| IL (1) | IL250888A0 (enExample) |
| MX (1) | MX2017002986A (enExample) |
| SG (2) | SG10201901189SA (enExample) |
| WO (1) | WO2016040515A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017527576A (ja) | 2014-09-10 | 2017-09-21 | エピザイム，インコーポレイティド | 置換シクロヘキシルアミン化合物 |
| US10428029B2 (en) | 2014-09-10 | 2019-10-01 | Epizyme, Inc. | Isoxazole carboxamide compounds |
| KR102496364B1 (ko) | 2014-09-10 | 2023-02-06 | 에피자임, 인코포레이티드 | Ｓｍｙｄ 억제제 |
| WO2016040511A1 (en) | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Isoxazole carboxamides as irreversible smyd inhibitors |
| CN115160248B (zh) * | 2015-02-27 | 2025-03-28 | 海洋规划生物工厂株式会社 | Kakeromycin及其衍生物的制造方法 |
| TWI691494B (zh) * | 2016-07-28 | 2020-04-21 | 瑞士商愛杜西亞製藥有限公司 | 哌啶衍生物 |
| WO2018151678A1 (en) * | 2017-02-15 | 2018-08-23 | Agency For Science, Technology And Research | Compounds for treatment of cancer and epigenetics |
| EP3743422B1 (en) * | 2018-01-26 | 2024-03-13 | Idorsia Pharmaceuticals Ltd | Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide |
| CN112955215B (zh) | 2018-10-29 | 2024-05-17 | 勃林格殷格翰国际有限公司 | 吡啶基磺酰胺衍生物、药物组合物及其用途 |
| WO2020089025A1 (en) | 2018-10-29 | 2020-05-07 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| AU2020360928A1 (en) | 2019-09-30 | 2022-04-14 | Nippon Chemiphar Co., Ltd. | Azepan derivative |
| CN114702552B (zh) * | 2022-03-11 | 2024-05-31 | 苏州思萃免疫技术研究所有限公司 | mTORC2抑制剂 |
| WO2024067708A1 (zh) * | 2022-09-30 | 2024-04-04 | 苏州阿尔脉生物科技有限公司 | 草酸胺类衍生物、包含其的药物组合物及其医药用途 |
| WO2025133989A1 (en) * | 2023-12-20 | 2025-06-26 | Alt-Bio Pte. Ltd. | Smyd modulators and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1228288B (it) * | 1989-01-09 | 1991-06-07 | Zambon Spa | Composti ad attivita' antiserotoninica |
| SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| SE0403106D0 (sv) | 2004-12-20 | 2004-12-20 | Astrazeneca Ab | Chemical compounds |
| WO2008137834A2 (en) * | 2007-05-04 | 2008-11-13 | Osi Pharmaceuticals, Inc. | Crystal structure of smyd3 protein |
| US8470816B2 (en) * | 2007-12-03 | 2013-06-25 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound and use thereof |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| JP5927201B2 (ja) * | 2010-12-16 | 2016-06-01 | カルチャン リミテッド | Ａｓｋ１阻害ピロロピリミジン誘導体 |
| WO2016040508A1 (en) | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Substituted pyrrolidine carboxamide compounds |
| US20170253601A1 (en) | 2014-09-10 | 2017-09-07 | Epizyme, Inc. | Substituted Pyrrolidine Compounds |
| KR102496364B1 (ko) | 2014-09-10 | 2023-02-06 | 에피자임, 인코포레이티드 | Ｓｍｙｄ 억제제 |
| US10428029B2 (en) | 2014-09-10 | 2019-10-01 | Epizyme, Inc. | Isoxazole carboxamide compounds |
| JP2017527576A (ja) | 2014-09-10 | 2017-09-21 | エピザイム，インコーポレイティド | 置換シクロヘキシルアミン化合物 |
| WO2016040511A1 (en) | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Isoxazole carboxamides as irreversible smyd inhibitors |
-
2015
- 2015-09-09 WO PCT/US2015/049235 patent/WO2016040515A1/en not_active Ceased
- 2015-09-09 BR BR112017004589A patent/BR112017004589A2/pt not_active Application Discontinuation
- 2015-09-09 MX MX2017002986A patent/MX2017002986A/es unknown
- 2015-09-09 CN CN201580060918.8A patent/CN107072207A/zh active Pending
- 2015-09-09 EA EA201790327A patent/EA201790327A1/ru unknown
- 2015-09-09 CA CA2960280A patent/CA2960280A1/en not_active Abandoned
- 2015-09-09 EP EP15840497.0A patent/EP3193605A4/en not_active Withdrawn
- 2015-09-09 AU AU2015315182A patent/AU2015315182A1/en not_active Abandoned
- 2015-09-09 KR KR1020177009316A patent/KR20170047397A/ko not_active Withdrawn
- 2015-09-09 US US15/510,588 patent/US10577363B2/en active Active
- 2015-09-09 JP JP2017513207A patent/JP2017528464A/ja active Pending
- 2015-09-09 SG SG10201901189SA patent/SG10201901189SA/en unknown
- 2015-09-09 SG SG11201701597RA patent/SG11201701597RA/en unknown
-
2017
- 2017-03-02 IL IL250888A patent/IL250888A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107072207A (zh) | 2017-08-18 |
| JP2017528464A (ja) | 2017-09-28 |
| KR20170047397A (ko) | 2017-05-04 |
| SG10201901189SA (en) | 2019-03-28 |
| US10577363B2 (en) | 2020-03-03 |
| WO2016040515A1 (en) | 2016-03-17 |
| SG11201701597RA (en) | 2017-03-30 |
| EP3193605A1 (en) | 2017-07-26 |
| BR112017004589A2 (pt) | 2018-01-23 |
| CA2960280A1 (en) | 2016-03-17 |
| EA201790327A1 (ru) | 2017-10-31 |
| AU2015315182A1 (en) | 2017-03-16 |
| EP3193605A4 (en) | 2018-04-18 |
| US20170362217A1 (en) | 2017-12-21 |
| MX2017002986A (es) | 2017-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250345A0 (en) | new compounds | |
| TWI561516B (en) | Substituted dihydroisoquinolinone compounds | |
| IL250592A0 (en) | new compounds | |
| GB201417011D0 (en) | Novel compounds | |
| GB201417094D0 (en) | Novel compounds | |
| IL250888A0 (en) | Transmuted piperidine compounds | |
| GB201405991D0 (en) | Novel compounds | |
| GB201417018D0 (en) | Novel compounds | |
| AP2016009432A0 (en) | Novel compounds | |
| GB201411236D0 (en) | Novel compounds | |
| GB201411239D0 (en) | Novel compounds | |
| GB201404002D0 (en) | Novel compounds | |
| IL248983A0 (en) | new compounds | |
| GB201419102D0 (en) | Novel compounds | |
| IL247327A0 (en) | new compounds | |
| GB201421834D0 (en) | Novel compounds | |
| GB201421784D0 (en) | Novel compounds | |
| GB201417041D0 (en) | Novel compounds | |
| GB201417021D0 (en) | Novel compounds | |
| GB201417043D0 (en) | Novel compounds | |
| GB201414614D0 (en) | Novel compounds | |
| GB201413451D0 (en) | Novel compounds | |
| GB201413260D0 (en) | Novel compounds | |
| GB201412689D0 (en) | Novel compounds | |
| PL3154977T3 (pl) | Nowe związki |